Solarvest Announces Closing of Debt Settlement

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



Vancouver, B.C. - TheNewswire - January 14, 2020 – Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS) announces that further to its news release dated January 6, 2021, it has received the TSX Venture Exchange Final Approval for the Shares for Debt Transaction whereby 525,000 Common Shares of the Company were issued in order to settle a debt of $73,500.

All Common Shares issued in connection with the Transaction are subject to resale restrictions for a period of four months and one day under applicable securities legislation.

About Solarvest:

Solarvest BioEnergy Inc. is a biologics company whose algae production platform provides it with an extremely flexible system capable of producing numerous products ranging from Omega 3 fatty acids to human therapeutic proteins. The company has produced the world’s first organic high DHA Omega-3 for the global supplement market and is launching its first finished product in the USA on Amazon and its e-commerce site.  These developed finished products will be offered to key retailers as house brands which will supply them a patented competitive advantage. The company has also successfully demonstrated the expression of a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.  

For further information contact:         

Gerri Greenham, Chief Executive Officer

Email: [email protected]

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company’s expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.